A Phase 3 interventional study of aspirin discontinuation and aspirin continuation in Preeclampsia and Perinatal Haemorrhage, sponsored by FANG HE. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by FANG HE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.
Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 26th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 22–40 · Women only
FANG HE · Sites in China
Ages 18–45 · Women only
Peking University Third Hospital · Sites in China
Ages 18–45 · Women only · Healthy volunteers
General Hospital of Ningxia Medical University · Sites in China
Ages 18–45 · Women only
The Third Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 180 across the 19 interventional studies, 1,000 across the 17 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 36 have an industry lead sponsor. The 10 most frequent:
FANG HE is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
FANG HE has 3 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pre-Eclampsia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06414655Peking University Third HospitalMulticenter Prospective Cohort Study of Twin Maternal-Child Dyads in China | 2026-11-30 |
| NCT07384936Fang WangTopefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia | 2027-05 |
| NCT06821685The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAutologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Pre-Eclampsia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.
This study aimed to optimize the strategy of aspirin to prevent preeclampsia, by exploring whether aspirin discontinuation at 28 weeks of gestation to prevent preterm PE is not inferior to 36 weeks of gestation. We will include pregnant women with normal NT scan who meet at least one high-risk factor or at least two medium-risk factors. During 12-16 weeks of gestation, the mean arterial pressure (MAP) and placental growth factor (PlGF) are measured, then initiating aspirin 100mg qn. At 24-27+6 weeks of gestation, the patients were 1:1 randomly divided into two groups, sFlt-1 and PlGF were detected at the same time. The experimental group discontinue aspirin at 28 weeks of gestation, and the control group receive aspirin until 36 weeks of gestation. The incidence of preterm PE in the two groups was compared by non-inferiority test, and the non-inferiority threshold was 2%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, discontinuing aspirin at 28 weeks of gestation.
Drug: aspirin discontinuation
initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, continuing aspirin until 36 weeks of gestation.
Drug: aspirin continuation
Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Also known as: initiation of aspirin in early pregnancy
Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Also known as: initiation of aspirin in early pregnancy
Incidence of preterm preeclampsia
delivery with preeclampsia before 37 weeks of gestation
Time frame: Within one week after delivery
Incidence of early-onset preeclampsia
delivery with preeclampsia before 34 weeks of gestation
Time frame: Within one week after delivery
Incidence of term preeclampsia
delivery with preeclampsia after 37 weeks of gestation
Time frame: Within one week after delivery
Incidence of gestational hypertension
new onset of high blood pressure after 20 weeks of gestation (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg)
Time frame: Within one week after delivery
Incidence of small for gestational age
birth weight below the 10th percentile
Time frame: Within one week after delivery
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
FANG HE